Senores Pharmaceuticals IPO Description – Senores Pharmaceuticals is a globally focused, research-driven pharmaceutical company specializing in developing and manufacturing a broad range of pharmaceutical products. With a strong presence in regulated and emerging markets, the company operates across various therapeutic areas and dosage forms. Its core strength lies in identifying, developing, and producing specialty, underpenetrated, and complex pharmaceutical products, positioning itself as a preferred partner for select customers.
The company has established partnerships in regulated markets with leading foreign and Indian pharmaceutical companies, including Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories, Sun Pharmaceuticals, Dr. Reddy’s Laboratories Inc., and Cipla USA Inc. Senores Pharmaceuticals primarily focuses on the regulated markets of the US and Canada while maintaining a presence in emerging markets across 43 countries, and has obtained product registrations for 205 products and has filed registrations for an additional 406 products.
The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs). As of 30 September 2024, the company had 145 employees on payroll.
Promoters of Senores Pharmaceuticals – Swapnil Jatinbhai Shah, and Ashok Kumar Vijaysinh Barot
Table of Contents
Senores Pharmaceuticals IPO Details
| Senores Pharmaceuticals IPO Dates | 20 – 24 December 2024 |
| Senores Pharmaceuticals Issue Price | INR 372 – 391 per share |
| Fresh issue | INR 500 crore |
| Offer For Sale | 21,00,000 shares (INR 78.12 – 82.11 crore) |
| Total IPO size | INR 578.12 – 582.11 crore |
| Minimum bid (lot size) | 38 shares (INR 14,858) |
| Face Value | INR 10 per share |
| Retail Allocation | 10% |
| Listing On | NSE, BSE |
Senores Pharmaceuticals Financial Performance
| Â | FY 2022 | FY 2023 | FY 2024 | H1 FY 2025 |
| Revenue | 14.17 | 35.34 | 214.52 | 181.02 |
| Expenses | 13.49 | 26.58 | 192.40 | 153.95 |
| Net income | 0.99 | 8.43 | 32.71 | 23.94 |
| Margin (%) | 6.99 | 23.85 | 15.25 | 13.23 |
Senores Pharmaceuticals Offer News
- Senores Pharmaceuticals RHP
- Senores Pharmaceuticals DRHP
- ASBA IPO Forms
- Live IPO Subscription Status
- IPO Allotment Status
Senores Pharmaceuticals Valuations & Margins
| FY 2022 | FY 2023 | FY 2024 (Pre Issue) | FY 2025 (Post-Issue)* | |
| EPS | 0.30 | 2.53 | 9.83 | 10.40 |
| PE Ratio | – | – | 37.83 – 39.76 | 35.77 – 37.60 |
| FY 2022 | FY 2023 | FY 2024 | |
| RONW (%) | 4.35 | 20.55 | 23.60 |
| NAV | 11.00 | 13.68 | 61.42 |
| ROCE (%) | 5.38 | 18.56 | 11.73 |
| EBITDA (%) | 17.03 | 46.28 | 20.70 |
| Debt/Equity | 0.39 | 1.34 | 1.07 |
Senores Pharmaceuticals IPO GMP Today (Daily Trend)
| Date | Day-wise IPO GMP | Kostak | Subject to Sauda |
| 28 December 2024 | 250 | – | 6,200 |
| 27 December 2024 | 240 | – | 6,000 |
| 26 December 2024 | 240 | – | 6,000 |
| 25 December 2024 | 222 | – | 5,700 |
| 24 December 2024 | 222 | – | 5,700 |
| 23 December 2024 | 195 | – | 5,200 |
| 21 December 2024 | 175 | – | 4,900 |
| 20 December 2024 | 150 | – | 4,300 |
| 19 December 2024 | 150 | – | 4,300 |
Senores Pharmaceuticals IPO Objectives
The company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:
- Funding the capital expenditure requirements by investment in one of its subsidiaries, Havix, for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility – INR 107 crore
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the company and the Subsidiaries, namely, Havix, Ratnatris, and SPI – INR 93.7 crore
- Funding the working capital requirements of the company and its subsidiaries – INR 102.74 crore
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes– INR NA crore
- General corporate purposes
Senores Pharmaceuticals IPO Subscription – Live Updates
| Category | QIB | NII | Retail | Employee | Total |
|---|---|---|---|---|---|
| Shares Offered | 45,93,216 | 23,19,879 | 15,46,586 | 75,000 | 85,34,681 |
| 24 Dec 2024 | 94.66 | 96.11 | 89.22 | 19.92 | 93.41 |
| 23 Dec 2024 | 0.35 | 24.63 | 38.41 | 10.14 | 13.93 |
| 20 Dec 2024 | 0.01 | 1.67 | 7.20 | 1.88 | 1.78 |
Shares allotted to anchor investors are not included in these calculations. Similarly, shares allotted to market makers, if any, are not part of these calculations.
Senores Pharmaceuticals – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Senores Pharmaceuticals | 37.60 | 10.40 | 23.60 | 61.42 | 214.52 |
| Ajanta Pharma | 34.37 | 64.77 | 23.47 | 281.60 | 4208.71 |
| Alembic Pharmaceuticals | 34.58 | 31.33 | 13.40 | 245.12 | 6228.63 |
| Caplin Point | 25.23 | 59.90 | 21.69 | 309.03 | 1694.1 |
| Gland Pharma | 43.73 | 46.90 | 9.26 | 529.65 | 5664.72 |
| Strides Pharma | – | (7.76) | (4.44) | 225.43 | 4051.12 |
Senores Pharmaceuticals IPO Allotment Status
Senores Pharmaceuticals IPO allotment status is now available on Link Intime’s website. Click on this link to get allotment status.
Senores Pharmaceuticals IPO Dates & Listing Performance
| IPO Opening Date | 20 December 2024 |
| IPO Closing Date | 24 December 2024 |
| Finalization of Basis of Allotment | 26 December 2024 |
| Initiation of refunds | 27 December 2024 |
| Transfer of shares to demat accounts | 27 December 2024 |
| Senores Pharmaceuticals IPO Listing Date | 30 December 2024 |
| Opening Price on NSE | INR 600 per share (up 53.45%) |
| Closing Price on NSE | INR 557.05 per share (up 42.47%) |
Senores Pharmaceuticals IPO Reviews – Subscribe or Avoid?
Aditya Birla Money – Subscribe
Anand Rathi – Subscribe
Antique Stock Broking –
Ajcon Global –
Arihant Capital –
Axis Capital –
Ashika Research –
BP Wealth – Subscribe
Capital Market – Neutral
Canara Bank Securities – Subscribe
Choice Broking –
Dalal & Broacha –
Elara Capital –
Elite Wealth – Not rated
GCL Broking –
Geojit –
GEPL Capital – Subscribe
Hem Securities –
Hensex Securities –
HDFC Securities –
ICICIdirect –
IDBI Capital –
Investmentz –
Indsec Securities –Â
Jainam Broking – Subscribe for listing gain
KR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Mehta Equities –
Nirmal Bang – Subscribe
Reliance Securities –
Sushil Finance –
Samco Securities – Subscribe for listing gain
SBI Securities – Subscribe for long term
SMC Global –
SMIFS –
Systematix Research –
Swastika Investmart –
Ventura Securities – Subscribe
Senores Pharmaceuticals Offer Lead Manager
EQUIRUS CAPITAL PRIVATE LIMITED
12th Floor, C Wing, Marathon Futurex,
N M Joshi Marg, Lower Parel,
Mumbai 400 013, Maharashtra
Phone: +91 22 4332 0735
Email:Â [email protected]
Website: www.equirus.com
Senores Pharmaceuticals Offer Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park L.B.S. Marg,
Vikhroli West, Mumbai – 400 083, Maharashtra
Tel:Â : +91 8108114949
E-mail:Â [email protected]
Website:Â www.linkintime.co.in
Senores Pharmaceuticals Contact Details
SENORES PHARMACEUTICALS LIMITED
1101 to 1103, 11th floor, South Tower, ONE 42
opposite Jayantilal Park, Ambali Bopal Road,
Ahmedabad, Ahmedabad, Gujarat, India
Phone:Â +91-79-29999857
Email: [email protected]
Website: www.senorespharma.com
Senores Pharmaceuticals IPO FAQs
How many shares in Senores Pharmaceuticals IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 75%, NII – 15%, and Retail – 10%.
How to apply for Senores Pharmaceuticals Public Offer?
The best way to apply for Senores Pharmaceuticals public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Senores Pharmaceuticals IPO GMP today?
Senores Pharmaceuticals IPO GMP today is INR 250 per share.
What is Senores Pharmaceuticals kostak rate today?
Senores Pharmaceuticals kostak rate today is INR NA per application.
What is Senores Pharmaceuticals Subject to Sauda rate today?
Senores Pharmaceuticals Subject to Sauda rate today is INR 6,200 per application.
